23andMe (NASDAQ:ME) Earns Sell (E+) Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 23andMe (NASDAQ:ME) in a report released on Saturday morning,Weiss Ratings reports.

23andMe Price Performance

Shares of NASDAQ ME opened at $1.79 on Friday. The stock has a market capitalization of $48.02 million, a PE ratio of -0.12 and a beta of 1.19. The business has a fifty day moving average price of $2.55 and a two-hundred day moving average price of $3.93. 23andMe has a fifty-two week low of $1.34 and a fifty-two week high of $12.76.

23andMe (NASDAQ:ME) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

Hedge Funds Weigh In On 23andMe

Several hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of 23andMe by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after purchasing an additional 28,252 shares during the last quarter. FMR LLC grew its position in 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock worth $345,000 after acquiring an additional 192,099 shares during the last quarter. Shay Capital LLC grew its position in 23andMe by 71.7% during the 4th quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock worth $2,283,000 after acquiring an additional 293,358 shares during the last quarter. Virtu Financial LLC bought a new stake in 23andMe during the 4th quarter worth $49,000. Finally, MassMutual Private Wealth & Trust FSB bought a new stake in 23andMe during the 4th quarter worth $40,000. Institutional investors own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.